Lyell Immunopharma, Inc. — Director's Dealing 2023

Aug 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2023-08-10

Reporting Person: Lang Matthew (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-10	Option (right to buy)	$2.31	A	2250000	Acquired	2033-08-09	Common Stock (2250000)	Direct

Footnotes

F1: 1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.